Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glivec in acute cervical spinal cord injury
NCT02363361Phase 2Unknown
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Spinal cord injury (SCI). Primary endpoints: Plasma levels of Imatinib at Day 19 and Serum cytokine levels at Day 19. Status: unknown.
02
Drugs
03
Conditions
Spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02363361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363361.